Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION.
Wechsler ME, Stolz D, Lugogo NL, Caveney S, Almqvist G, Bednarczyk A, Kotalik A, Chandarana S, Ambrose CS. Wechsler ME, et al. Among authors: bednarczyk a. J Allergy Clin Immunol Pract. 2024 Nov;12(11):3128-3131.e2. doi: 10.1016/j.jaip.2024.08.008. Epub 2024 Aug 8. J Allergy Clin Immunol Pract. 2024. PMID: 39127103 Free article. No abstract available.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: bednarczyk a. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential.
Aurivillius M, Bednarczyk A, Kokot M, Madriaga J, Mei J, Collison K, Surujbally R, Archbell J, Joshi V, Gillen M. Aurivillius M, et al. Among authors: bednarczyk a. Pulm Pharmacol Ther. 2023 Dec;83:102245. doi: 10.1016/j.pupt.2023.102245. Epub 2023 Aug 20. Pulm Pharmacol Ther. 2023. PMID: 37607661 Free article. Clinical Trial.
Multiglandular Parathyroid Disease.
Kowalski G, Buła G, Bednarczyk A, Gawrychowska A, Gawrychowski J. Kowalski G, et al. Among authors: bednarczyk a. Life (Basel). 2022 Aug 22;12(8):1286. doi: 10.3390/life12081286. Life (Basel). 2022. PMID: 36013465 Free PMC article.
Parathyroid carcinoma - a study of 29 cases.
Kowalski GJ, Bednarczyk A, Buła G, Gawrychowska A, Gawrychowski J. Kowalski GJ, et al. Among authors: bednarczyk a. Endokrynol Pol. 2022;73(1):56-63. doi: 10.5603/EP.a2022.0003. Epub 2022 Feb 14. Endokrynol Pol. 2022. PMID: 35156702 Free article.
Primary hyperparathyroidism due to mediastinal parathyroid lesions.
Gawrychowski J, Buła G, Niedzielski Z, Gawrychowska A, Bednarczyk A, Kowalski G. Gawrychowski J, et al. Among authors: bednarczyk a. Kardiochir Torakochirurgia Pol. 2021 Mar;18(1):55-59. doi: 10.5114/kitp.2021.105189. Epub 2021 May 15. Kardiochir Torakochirurgia Pol. 2021. PMID: 34552645 Free PMC article. No abstract available.
37 results